Literature DB >> 1707753

Preferential expression of c-kit protooncogene transcripts in small cell lung cancer.

Y Sekido1, Y Obata, R Ueda, T Hida, M Suyama, K Shimokata, Y Ariyoshi, T Takahashi.   

Abstract

As an initial step to understand rapid growth of small cell lung cancer (SCLC), a complementary DNA library prepared from a SCLC cell line was screened with viral oncogene probes encoding protein-tyrosine kinases, which are known to play an important role in regulation of cell growth. Fifteen clones hybridizing with v-fms probe were isolated, and, by partial sequence analysis, four of them were identified to be c-kit protooncogenes. Northern blot study demonstrated that most of the SCLC tumors and cell lines expressed c-kit transcripts, while non-SCLC tumors and cell lines did not. Neither amplification nor rearrangement of the c-kit gene was demonstrated in SCLC cell lines by Southern blot analysis, however. Our results suggested that c-kit expression in SCLC reflects the unique biological nature of the tumor cells different from non-SCLC and further suggested that the c-kit product may participate in autocrine or paracrine stimulation of SCLC growth.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1707753

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

Review 1.  The impact of surgery on the multidisciplinary treatment of bronchogenic small cell carcinoma (updated review including ongoing studies).

Authors:  W Theuer; O Selawry; K Karrer
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

2.  Complex intrachromosomal rearrangement in the process of amplification of the L-myc gene in small-cell lung cancer.

Authors:  Y Sekido; T Takahashi; T P Mäkelä; Y Obata; R Ueda; T Hida; K Hibi; K Shimokata; K Alitalo; T Takahashi
Journal:  Mol Cell Biol       Date:  1992-04       Impact factor: 4.272

Review 3.  Second-line treatment of small-cell lung cancer.

Authors:  Cecilia MacCallum; Heidi H Gillenwater
Journal:  Curr Oncol Rep       Date:  2006-07       Impact factor: 5.075

Review 4.  Small cell lung cancer: therapies and targets.

Authors:  Rathi N Pillai; Taofeek K Owonikoko
Journal:  Semin Oncol       Date:  2013-12-12       Impact factor: 4.929

Review 5.  A clinical and biological overview of gastrointestinal stromal tumors.

Authors:  Myrna Candelaria; Jaime de la Garza; Alfonso Duenas-Gonzalez
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

6.  A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).

Authors:  Antonius A Miller; Herbert Pang; Lydia Hodgson; Nithya Ramnath; Gregory A Otterson; Michael J Kelley; Robert A Kratzke; Everett E Vokes
Journal:  J Thorac Oncol       Date:  2010-03       Impact factor: 15.609

7.  Follicular expression of c-Kit/SCF and inhibin-alpha in mouse ovary during development.

Authors:  Jae Seong Kang; Chang Joo Lee; Jong Min Lee; Joong Yeol Rha; Kang Won Song; Moon Hyang Park
Journal:  J Histochem Cytochem       Date:  2003-11       Impact factor: 2.479

8.  Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.

Authors:  T Furitsu; T Tsujimura; T Tono; H Ikeda; H Kitayama; U Koshimizu; H Sugahara; J H Butterfield; L K Ashman; Y Kanayama
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

9.  CD117 immunoreactivity in high-grade neuroendocrine tumors of the lung: a comparative study of 39 large-cell neuroendocrine carcinomas and 27 surgically resected small-cell carcinomas.

Authors:  Giuseppe Pelosi; Michele Masullo; Maria Elena Leon; Giulia Veronesi; Lorenzo Spaggiari; Felice Pasini; Angelica Sonzogni; Antonio Iannucci; Enrica Bresaola; Giuseppe Viale
Journal:  Virchows Arch       Date:  2004-09-16       Impact factor: 4.064

10.  Expression and mutational analysis of c-kit in ovarian surface epithelial tumors.

Authors:  Dong-Ja Kim; Myung-Hoon Lee; Tae-In Park; Han-Ik Bae
Journal:  J Korean Med Sci       Date:  2006-02       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.